Similar to solid tumors, a subpopulation of MM cells was shown to demonstrate cancer stem-cell-like properties by showing clonotypic properties, 3 drug resistance and high drug efflux capacity, 3 and EMT-like phenotype. 8 Tumor hypoxia was shown to develop during MM progression and to be crucial for metastasis. 8, 9 Hypoxia was previously shown to induce the acquisition of EMTlike phenotype; 8 and to promote less mature phenotype by the downregulation of plasma cell factors (IRF4, PRDM1 and XBP1) and upregulation of B-cell-(BCL6 and PAX5) and stem cell transcription factors (Oct4, NANOG, SOX2).
10 CD138 (syndecan-1, a heparin sulfate proteoglycan) is the gold standard for diagnosis; 11 however, previous studies showed that MM contains a subpopulation of cells that are CD138-negative, clonotypic, drug resistant, and show stem cell-like properties, express drug efflux pump, 12 and display higher clonogenic potential than CD138+ in vivo. 13 However, the molecular mechanisms leading to the development of this CD138-negative population and the activation of the stemcell signaling pathways in them is not yet understood.
In this study, we investigated the effect of hypoxia on the acquisition of stem cell-like properties such as early-differentiation markers, G1-arrest, quiescent phenotype, capability of tumor initiation in vivo and drug resistance in MM cells.
To investigate the effect of hypoxia on the differentiation status of MM cells, five MM cell lines were cultured under normoxic (21% O 2 ) and hypoxic conditions (in hypoxic chamber; 1% O 2 ) for 48 h, and the expression of plasma cell marker (CD138), B-cell markers (CD19, CD20 and CD45) and hematopoietic stem cell marker (CD34) were tested. Consistently with previous studies, 10 it was found that hypoxic MM cells expressed~50% less plasma cell marker CD138 compared with normoxic conditions. On the contrary, B-cell markers such as CD20 and CD45 were increased by hypoxia, with no effect on CD19 expression. Moreover, stem cell marker CD34 was increased during hypoxia in MM cells (Figure 1a) . These results confirmed that hypoxia induces immature phenotype in myeloma cells in which it decreased the expression of terminal differentiation markers (CD138) and increased the expression of B-cell and stem cell markers.
We further analyzed the effect of hypoxia on cell proliferation and cell cycle in MM cells. MM cells were cultured in hypoxic and normoxic conditions, and their proliferation and associated cell signaling was analyzed. Hypoxia decreased the proliferation of MM cells by 10-20% (Figure 1b) , which was associated with decreased activation of the PI3K signaling (p-PI3K-P85, p-AKT and p-mTOR), whereas stress kinases such as p-MKK3/6 and p-P38 were increased in hypoxia (Figure 1c ). The reduced proliferation in hypoxia was facilitated through a G1-cell cycle arrest, with decreased synthesis of DNA (S phase) in all three cell lines (Figure 1d ), which was associated with the downregulation in the expression of proteins involved in cell cycle transition from G1 to S phase, including cyclin-D1, cyclin-D2, cyclin-D3, cyclin-E and pRb, whereas the cell cycle inhibitor p27 was increased (Figure 1e) . In addition, we tested the effect of hypoxia on cell apoptosis and found that both normoxic and hypoxic cells had similar percentage of apoptotic (APO 2.7-positive) cells (Figure 1f ). Unchanged apoptosis was confirmed by immunoblotting showing a lack of induction of caspase-3 and caspase-9 cleavage, and unchanged expression of pro-and antiapoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 (Figure 1g ). These results suggest that hypoxia induces a quiescent state of cancer cells with no signs of cell apoptosis.
Moreover, we tested the effect of hypoxia on the ability of MM1s-GFP-Luc cells to initiate tumor in vivo. MM cells were incubated in hypoxia or normoxia for 24 h in vitro and these were injected via tail vein to SCID (severe combined immunodeficiency) mice, which were followed by bioluminescence imaging for tumor progression. It was found that hypoxia enhanced the tumor initiation ability of MM cells, in which at week 3 the signal appeared first in the mice injected with hypoxic cells but not in animals injected with normoxic cells. Moreover, over the next 2 weeks the mice injected with hypoxic cells demonstrated higher tumor burden (Figures 2a and b) . These findings can be attributed to the more efficient homing of hypoxic cells to the BM, as we previously described. 8 Similar results were previously obtained when stem cell-like MM cells (identified as CD138-/CD34+) induced MM tumors in vivo faster and to a higher tumor burden compared with CD138+/CD34-MM cells. Letter to the Editor cells. 14 Hypoxia was shown to decrease ROS production; [15] [16] [17] therefore we suggest that this could be a potential mechanism of resistance to proteasome inhibitors in hypoxia in MM cells. In general, these results on stem cell drug resistance are in accord with previous reports showing that myeloma stem cell-like cells (defined as CD138-CD19+CD27+) had an increased activity of aldehyde dehydrogenase (ALDH1), and increased the expression of drug efflux pumps such as ABCG2, ALDH1 and RARα2, conferring chemoresistance to bortezomib, dexamethasone and lenalidomide. 3 Moreover, the CD138-negative subpopulation of 5T33MM and 5TGM1 cells was also more resistant to melphalan and lenalidomide than CD138+ cells. 18 The hypoxic phenotype of MM cells was shown to be reversible after reoxygenation. We have previously demonstrated that hypoxic MM cells recovered, as soon as, 6 h after the exposure to medium from normoxic stroma. 8 In addition, we have recently demonstrated that reoxygenation of hypoxic Waldenström's macroglobulinemia cells reversed their hypoxic phenotype by restoring cell proliferation rate, inducing the exit of the G1-arrest, and restoring E-cadherin expression and adhesion to stromal cells. 19 Moreover, the expression of the main plasma cell marker CD138, which is decreased by hypoxia, also recovered after reoxygenation in MM cells. 10 In summary, hypoxia induced MM cell dedifferentiation; acquisition of a quiescent state by decreasing proliferation and inducing G1-cell cycle arrest, but without altering apoptosis; enhanced tumor initiation; and increased drug resistance to proteasome inhibitors. On the basis of these findings we propose to target hypoxic cells to diminish the stem cell-like population, in order to decrease microresidual disease and ultimately prevent recurrence in MM patients.
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